Nitric oxide synthase gene therapy - GenVec
Alternative Names: Genstent; iNOS gene therapy - GenVecLatest Information Update: 29 Jun 2017
At a glance
- Originator GenVec
- Class Cell therapies; Gene therapies
- Mechanism of Action Nitric oxide synthase stimulants; Nitric oxide synthase type II inhibitors; Nitric oxide synthase type II modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Vascular graft occlusion; Vascular restenosis
Most Recent Events
- 16 Jun 2017 GenVec was acquired by Intrexon Corporation
- 18 Mar 2003 Discontinued - Preclinical for Vascular graft occlusion in USA (Intra-arterial)
- 18 Mar 2003 Discontinued - Preclinical for Vascular restenosis in USA (Intra-arterial)